SecBot SecBot
SECBOTREPLAY Home › Report › VTVT

VTVT · vTv Therapeutics reported Q4 and full-year 2025 financial results,…

vTv Therapeutics Inc. · PRESS-RELEASE filed Mar 10, 2026 at 16:01 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 10, 2026 at 16:01 ET

vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a significant cash increase to $88.9 million from an $80 million financing and a $20 million upfront payment from Newsoara under an amended licensing deal. The company expects to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin in Q3 2026, with a funding runway extending beyond the topline readout. However, net losses widened year-over-year due to higher R&D and G&A expenses.

  • Received $20.0 million upfront from Newsoara in February 2026 under an amended licensing agreement for global rights to PDE4 inhibitor HPP737.
  • Cash position was $88.9 million as of December 31, 2025, up from $36.7 million a year prior, driven by $80 million private placement and licensing proceeds.
  • Net loss for Q4 2025 was $7.1 million vs. $3.6 million in Q4 2024; full-year 2025 net loss was $27.0 million vs. $18.5 million in 2024.
  • R&D expenses increased to $17.9 million in 2025 from $11.5 million in 2024, primarily due to cadisegliatin clinical trials.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access